Alcon Inc. (SWX:ALC)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
81.54
-0.22 (-0.27%)
Mar 25, 2025, 5:32 PM CET
8.84%
Market Cap 40.33B
Revenue (ttm) 8.98B
Net Income (ttm) 922.49M
Shares Out 494.62M
EPS (ttm) 1.86
PE Ratio 43.89
Forward PE 28.52
Dividend 0.28 (0.34%)
Ex-Dividend Date May 14, 2024
Volume 795,801
Average Volume 1,088,831
Open 82.18
Previous Close 81.76
Day's Range 81.04 - 82.44
52-Week Range 70.90 - 87.00
Beta 0.83
RSI 53.87
Earnings Date Feb 27, 2025

About Alcon

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]

Sector Healthcare
Founded 1945
Employees 25,599
Stock Exchange SIX Swiss Exchange
Ticker Symbol ALC
Full Company Profile

Financial Performance

In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.

Financial numbers in USD Financial Statements

News

Alcon Inc (ALC) Launches Clareon Vivity IOL in Europe

Alcon Inc (ALC) Launches Clareon Vivity IOL in Europe

19 hours ago - GuruFocus

Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

GENEVA--(BUSINESS WIRE)--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities.

21 hours ago - Business Wire

Alcon Eyes Surgical Edge With LENSAR Buyout: Details

Alcon is set to acquire LENSAR Inc. in a ... Full story available on Benzinga.com

1 day ago - Benzinga

Alcon Agrees to Acquire LENSAR, Inc.

GENEVA, Switzerland & ORLANDO, Fla.--(BUSINESS WIRE)--Alcon Agrees to Acquire LENSAR, Inc.

1 day ago - Business Wire

Retinal Surgery Devices Market Outlook Report 2025-2033: Revenues Set to Double, Reaching $4.83 Billion by 2033, Led by Topcon Corp., Alcon, and Carl Zeiss

Dublin, March 24, 2025 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offerin...

1 day ago - GlobeNewsWire

Alcon to Host 2025 Capital Markets Day

GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.

12 days ago - Business Wire

Alcon to Host 2025 Capital Markets Day

GENEVA--(BUSINESS WIRE)--Alcon to Host 2025 Capital Markets Day.

12 days ago - Business Wire

Alcon Stock Gets Relative Strength Rating Lift

A Relative Strength Rating upgrade for Alcon shows improving technical performance. Will it continue?

21 days ago - Investor's Business Daily

Alcon Inc (ALC) Expands TOTAL30® for Astigmatism Contact Lens Parameters

Alcon Inc (ALC) Expands TOTAL30® for Astigmatism Contact Lens Parameters

26 days ago - GuruFocus

Alcon Canada Strengthens its Commitment to Astigmatic Patients with TOTAL30 for Astigmatism Expanded Parameters

TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the availability of expanded parameters for TOTAL30® for Ast...

26 days ago - Business Wire

Watch CNBC's full interview with Alcon CEO David Endicott

Alcon CEO David Endicott discusses the pharmaceutical firm's full-year results.

27 days ago - CNBC International TV

Watch CNBC's full interview with Alcon CEO David Endicott

Alcon CEO David Endicott discusses the pharmaceutical firm's full-year results.

27 days ago - CNBC

Alcon eyes revenue growth in 2025 after in-line results

Alcon forecast sales of between $10.2 and $10.4 billion for 2025, after the eye care group reported higher fourth-quarter revenue underpinned by its surgical division on Tuesday.

27 days ago - Reuters

Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation

GENEVA--(BUSINESS WIRE)--Alcon Reports Full-Year 2024 Results, with Strong Top-line and Earnings Growth and Record Cash Generation.

4 weeks ago - Business Wire

Alcon Inc (ALC) Launches SYSTANE PRO Preservative-Free Eye Drops in the U.S.

Alcon Inc (ALC) Launches SYSTANE PRO Preservative-Free Eye Drops in the U.S.

4 weeks ago - GuruFocus

Alcon Inc. Q4 2024 Earnings Preview

4 weeks ago - Seeking Alpha

Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief With Its Longest Lasting Formula Yet

GENEVA--(BUSINESS WIRE)--Alcon Announces U.S. Launch of New SYSTANE PRO Preservative-Free, Revolutionizing Dry Eye Relief with Its Longest Lasting Formula Yet.

4 weeks ago - Business Wire

Alcon Inc (ALC) Launches Voyager™ DSLT in the U.S., Revolutionizing Glaucoma Treatment

Alcon Inc (ALC) Launches Voyager™ DSLT in the U.S., Revolutionizing Glaucoma Treatment

4 weeks ago - GuruFocus